Research Analysis Reports EPO Biosimilars - The Future of Erythropoietin Mar

EPO Biosimilars - The Future of
Erythropoietin Market Research Report to
2022
“"EPO Biosimilars - The Future of Erythropoietin
Market", the global erythropoietin market is
anticipated to reach an approximate value of US$ 7
Billion by 2020. This report provides a detailed
analysis of the current and future market scenario of
the global erythropoietin market.”
Erythropoietin is a hormone produced by healthy kidneys. This hormone prompts the bone marrow
to make the red blood cells, which then carry oxygen throughout the body. Erythropoietin is used to
treat anemia resulting from kidney failure or cancer treatment. It is considered to be an alternative
to blood transfusions. Over the last few years, the global erythropoietin industry has been showing
a sluggish growth due to patent expiry of biologic drugs. However, the biosimilar versions of these
drugs are expected to witness precipitous growth owing to their low cost.
Browse Full Research Report @: http://www.radiantinsights.com/research/epo-
biosimilars-the-future-of-erythropoietin-market
"EPO Biosimilars - The Future of Erythropoietin Market", the global erythropoietin market is
anticipated to reach an approximate value of US$ 7 Billion by 2020. This report provides a detailed
analysis of the current and future market scenario of the global erythropoietin market. The report
highlights biosimilar erythropoietin at various stages of clinical development.
Follow Us: